K
Kathy D. Miller
Researcher at Indiana University
Publications - 381
Citations - 22415
Kathy D. Miller is an academic researcher from Indiana University. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 65, co-authored 343 publications receiving 20068 citations. Previous affiliations of Kathy D. Miller include Regenstrief Institute & American Society of Clinical Oncology.
Papers
More filters
Journal ArticleDOI
Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer
Kathy D. Miller,Molin Wang,Julie Gralow,Maura N. Dickler,Melody A. Cobleigh,Edith A. Perez,Tamara Shenkier,David Cella,David Cella,Nancy E. Davidson +9 more
TL;DR: Initial therapy of metastatic breast cancer with paclitaxel plus bevacizumab prolongs progression-free survival, but not overall survival, as compared with pac litaxel alone.
Journal ArticleDOI
Randomized Phase III Trial of Capecitabine Compared With Bevacizumab Plus Capecitabine in Patients With Previously Treated Metastatic Breast Cancer
Kathy D. Miller,Linnea I. Chap,Frankie A. Holmes,Melody A. Cobleigh,P. Kelly Marcom,Louis Fehrenbacher,Maura N. Dickler,Beth Overmoyer,James D. Reimann,Amy P. Sing,Virginia K. Langmuir,Hope S. Rugo +11 more
TL;DR: Although the addition of bevacizumab to capecitabine produced a significant increase in response rates, this did not translate into improved PFS or overall survival.
Journal ArticleDOI
Arterial Thromboembolic Events in Patients with Metastatic Carcinoma Treated with Chemotherapy and Bevacizumab
Frank A. Scappaticci,Jamey R. Skillings,S. N. Holden,Hans-Peter Gerber,Kathy D. Miller,Fairooz F. Kabbinavar,Emily K. Bergsland,James Ngai,Eric Holmgren,Jiuzhou Wang,Herbert Hurwitz +10 more
TL;DR: Combination treatment with bevacizumab and chemotherapy, compared with chemotherapy alone, was associated with an increased risk of arterial thromboembolism but not venous thrombosis, and Baseline or on-study aspirin use wasassociated with modest increases in grade 3 and 4 bleeding events.
Journal ArticleDOI
NF-κ B Promotes Breast Cancer Cell Migration and Metastasis by Inducing the Expression of the Chemokine Receptor CXCR4
Gregory M. Helbig,Kent W. Christopherson,Poornima Bhat-Nakshatri,Suresh M. Kumar,Hiromitsu Kishimoto,Kathy D. Miller,Hal E. Broxmeyer,Harikrishna Nakshatri +7 more
TL;DR: It is demonstrated that NF-κB regulates the motility of breast cancer cells by directly up-regulating the expression of CXCR4 and the SDF-1α-mediated migration is observed with cancer cells that metastasized to the lungs.
Journal ArticleDOI
Association of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor-2 Genetic Polymorphisms With Outcome in a Trial of Paclitaxel Compared With Paclitaxel Plus Bevacizumab in Advanced Breast Cancer: ECOG 2100
Bryan P. Schneider,Molin Wang,Milan Radovich,George W. Sledge,Sunil Badve,Ann D. Thor,David A. Flockhart,Bradley A. Hancock,Nancy E. Davidson,Julie R. Gralow,Maura N. Dickler,Edith A. Perez,Melody A. Cobleigh,Tamara Shenkier,Susan M. Edgerton,Kathy D. Miller +15 more
TL;DR: The data support an association between VEGF genotype and median OS as well as grade 3 or 4 hypertension when using bevacizumab in metastatic breast cancer.